CAR-T therapy Yescarta reduces risk of death by more than 27%
Drug Discovery World
NOVEMBER 15, 2023
New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment in nearly 30 years to show statistically significant OS, with a median follow-up of 47.2 months.
Let's personalize your content